Our primary focus at Milestone is preparing for potential FDA approval of CARDAMYST nasal spray for the management of PSVT,” said ...

Boston Scientific expects to complete enrollment in the coming months in the study comparing pulsed field ablation to ...

Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the third quarter ended September 30, 2024 and provided a corporate update. “Our primary focus at Milestone is ...

The study, led by New York University Langone Health researchers who looked at data from more than 6,000 Fitbit users who ...

New research finds that on extremely hot days, people with implanted defibrillators face nearly triple the odds for a ...

Exposure to extreme heat may double or triple the risk of irregular heart rhythms in people with implanted defibrillators, ...

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy.

The findings build on prior evidence suggesting that exercise, even at minimum recommended levels, is protective against ...

Severe temperature spikes may double or triple the risk of irregular heart rhythm in people with implanted defibrillators. An analysis of health data for more than 2,000 people with implantable ...

Atrial fibrillation, or AFib is the most common type of heart arrhythmia. A new type of procedure is helping get hearts back on beat.

Boston Scientific is resuming its "Avant Guard" study of pulse field ablation (PFA) as a first-line therapy for atrial ...

More than six million Americans experience atrial fibrillation, or Afib, each year. Penn Stare Health Heart and Vascular is now offering a new, very focused and safe approach to treating Afib, ...